FY Results 2023
0:55
Our strategy
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, respiratory/immunology and oncology
Infectious diseases
1 in 3
of us will be affected by shingles in our lifetime
Respiratory/Immunology
25yrs
of leading research to help people with inflammatory conditions
Oncology
~10m
people died from cancer in 2020, making it a leading cause of death worldwide
Behind the science
Discover how we're getting ahead
‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
‘Adult vaccination plays an essential role in healthy ageing, so let’s prioritise prevention and make it a new standard of care’
In the face of climate change, vaccines play a crucial but underestimated role
'Prevention is the best medicine to stop disease before it starts'
The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
‘It can get very serious, very quickly’: the symptoms, risks, and ways to prevent pneumonia everyone should know about
‘You can’t be what you can’t see’: Why diversity in STEM is key to greater medical innovation
Outstanding people
INNOVATING TOGETHER 2022
Meet Euan: using technology in drug discovery
INNOVATING TOGETHER 2022
Meet Mugdha: working together to help more patients
INNOVATING TOGETHER 2022
Meet Pal: combining the power of genetics and genomics
WORKING TOGETHER
Meet P.J.: how a life-changing diagnosis changed his career
WORKING TOGETHER
Meet Jess: advocating for patients
WORKING TOGETHER
Meet Fiona: improving health and wellbeing through nature
In the spotlight
INVESTORS
We announced our full year and fourth quarter 2023 results on Wednesday 31 January